Analysis of Short-term (Operating) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Bristol-Myers Squibb Co., short-term (operating) activity ratios
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An analysis of short-term operating activity ratios reveals several noteworthy trends between 2021 and 2025. Generally, the period demonstrates fluctuations in efficiency metrics, with a noticeable shift in performance around 2022 and 2023, followed by some recovery in later years. Inventory management, accounts receivable handling, and accounts payable strategies all exhibit distinct patterns.
- Inventory Management
- Inventory turnover decreased from 4.74 in 2021 to a low of 4.02 in 2023, indicating a slowing pace of inventory sales. However, the ratio increased to 5.46 in 2024 and remained relatively stable at 5.18 in 2025, suggesting improved inventory management in the latter part of the period. Correspondingly, the average inventory processing period lengthened from 77 days in 2021 to 91 days in 2023, before decreasing to 67 days in 2024 and stabilizing at 70 days in 2025. This suggests a build-up of inventory followed by a more efficient flow.
- Receivables Management
- Receivables turnover experienced a decline from 5.65 in 2021 to 4.93 in 2023, indicating a slower collection of receivables. It partially recovered to 5.19 in 2024 and then decreased slightly to 4.87 in 2025. The average receivable collection period increased from 65 days in 2021 to 74 days in 2023, and then increased further to 75 days in 2025, suggesting a lengthening of the time required to collect payments from customers.
- Payables Management
- Payables turnover showed a modest increase from 3.37 in 2021 to 3.90 in 2025, indicating a slightly faster rate of paying suppliers. The average payables payment period decreased from 108 days in 2021 to 94 days in both 2024 and 2025, suggesting improved management of payment terms with suppliers.
- Overall Operating Efficiency
- Working capital turnover exhibited significant volatility. It increased dramatically from 3.95 in 2021 to 8.30 in 2022, before decreasing to 4.60 in 2023 and recovering to 7.79 and 7.83 in 2024 and 2025, respectively. This suggests a substantial shift in the utilization of working capital, potentially linked to changes in sales volume or operating strategies. The operating cycle lengthened from 142 days in 2021 to 165 days in 2023, then shortened to 137 days in 2024 and increased slightly to 145 days in 2025. The cash conversion cycle followed a similar pattern, increasing from 34 days in 2021 to 54 days in 2023, decreasing to 43 days in 2024, and increasing to 51 days in 2025.
In summary, the period under review was characterized by initial declines in key efficiency ratios, particularly in 2022 and 2023, followed by partial recoveries in 2024 and 2025. The fluctuations in working capital turnover and the cash conversion cycle suggest dynamic changes in the company’s operational strategies and financial management practices.
Turnover Ratios
Average No. Days
Inventory Turnover
Bristol-Myers Squibb Co., inventory turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of products sold, excludes amortization of acquired intangible assets | 13,936) | 13,968) | 10,693) | 10,137) | 9,940) | |
| Inventories | 2,690) | 2,557) | 2,662) | 2,339) | 2,095) | |
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | 5.18 | 5.46 | 4.02 | 4.33 | 4.74 | |
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | 3.68 | 4.04 | 4.98 | 4.87 | 5.58 | |
| Amgen Inc. | 1.93 | 1.84 | 0.89 | 1.30 | 1.58 | |
| Danaher Corp. | 4.04 | 4.15 | 3.80 | 4.03 | 4.16 | |
| Eli Lilly & Co. | 0.80 | 1.11 | 1.23 | 1.54 | 1.88 | |
| Gilead Sciences Inc. | 3.51 | 3.66 | 3.64 | 3.75 | 4.08 | |
| Johnson & Johnson | 2.13 | 2.21 | 2.37 | 2.49 | 2.87 | |
| Merck & Co. Inc. | 2.46 | 2.49 | 2.54 | 2.95 | 2.29 | |
| Pfizer Inc. | 1.51 | 1.65 | 2.45 | 3.82 | 3.40 | |
| Regeneron Pharmaceuticals Inc. | 0.66 | 0.64 | 0.70 | 0.65 | 1.25 | |
| Thermo Fisher Scientific Inc. | 4.85 | 5.06 | 5.06 | 4.60 | 3.88 | |
| Vertex Pharmaceuticals Inc. | 0.98 | 1.27 | 1.71 | 2.35 | 2.56 | |
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 2.23 | 2.46 | 2.55 | 3.06 | 3.11 | |
| Inventory Turnover, Industry | ||||||
| Health Care | 7.55 | 7.56 | 7.36 | 7.85 | 7.90 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Inventory turnover = Cost of products sold, excludes amortization of acquired intangible assets ÷ Inventories
= 13,936 ÷ 2,690 = 5.18
2 Click competitor name to see calculations.
The inventory turnover ratio exhibited a fluctuating pattern over the five-year period. Initially, the ratio decreased from 2021 to 2023, before increasing significantly in 2024 and experiencing a slight decline in 2025.
- Inventory Turnover Trend
- The inventory turnover ratio began at 4.74 in 2021. A consistent decline was observed in subsequent years, reaching a low of 4.02 in 2023. This suggests a lengthening of the time it took to sell inventory during this period. However, a substantial increase to 5.46 occurred in 2024, indicating a significantly improved efficiency in inventory management. The ratio then decreased modestly to 5.18 in 2025.
- Cost of Products Sold
- The cost of products sold increased steadily from 2021 to 2024, rising from US$9,940 million to US$13,968 million. This represents a substantial increase in the cost associated with producing and selling goods. In 2025, the cost of products sold experienced a slight decrease to US$13,936 million, indicating a potential stabilization or minor reduction in production costs.
- Inventory Levels
- Inventories increased from US$2,095 million in 2021 to US$2,662 million in 2023, suggesting a build-up of inventory over this timeframe. A decrease was noted in 2024, with inventories falling to US$2,557 million. Inventory levels then increased again in 2025, reaching US$2,690 million. These fluctuations in inventory levels likely influenced the observed trends in the inventory turnover ratio.
The increase in inventory turnover in 2024, coupled with the elevated cost of products sold, suggests a potentially successful strategy to move a higher volume of goods, despite increased production costs. The slight decrease in the ratio in 2025, alongside a minor reduction in the cost of products sold, warrants further investigation to determine if this represents a temporary fluctuation or the beginning of a new trend.
Receivables Turnover
Bristol-Myers Squibb Co., receivables turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net product sales | 46,756) | 46,778) | 43,778) | 44,671) | 45,055) | |
| Net trade receivables | 9,592) | 9,012) | 8,882) | 8,151) | 7,979) | |
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | 4.87 | 5.19 | 4.93 | 5.48 | 5.65 | |
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 4.86 | 5.16 | 4.87 | 5.16 | 5.63 | |
| Amgen Inc. | 3.67 | 4.72 | 3.70 | 4.46 | 4.96 | |
| Danaher Corp. | 6.28 | 6.75 | 6.09 | 6.40 | 6.36 | |
| Eli Lilly & Co. | 3.67 | 4.09 | 3.75 | 4.14 | 4.24 | |
| Gilead Sciences Inc. | 5.89 | 6.47 | 5.78 | 5.65 | 6.01 | |
| Johnson & Johnson | 5.48 | 5.98 | 5.73 | 5.88 | 6.14 | |
| Merck & Co. Inc. | 5.52 | 6.24 | 5.81 | 6.27 | 5.28 | |
| Pfizer Inc. | 5.27 | 5.55 | 5.33 | 9.24 | 7.16 | |
| Regeneron Pharmaceuticals Inc. | 2.50 | 2.29 | 2.31 | 2.28 | 2.66 | |
| Thermo Fisher Scientific Inc. | 5.01 | 5.23 | 5.21 | 5.53 | 4.92 | |
| Vertex Pharmaceuticals Inc. | 5.85 | 6.85 | 6.31 | 6.19 | 6.66 | |
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.79 | 5.26 | 4.96 | 5.76 | 5.54 | |
| Receivables Turnover, Industry | ||||||
| Health Care | 7.58 | 7.97 | 7.66 | 8.22 | 8.00 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Receivables turnover = Net product sales ÷ Net trade receivables
= 46,756 ÷ 9,592 = 4.87
2 Click competitor name to see calculations.
An examination of the provided financial information reveals trends in receivables turnover over a five-year period. Net product sales experienced a slight decrease from 2021 to 2022, followed by continued declines in 2023, before increasing in both 2024 and 2025, remaining relatively stable between those two years. Net trade receivables consistently increased throughout the period, exhibiting the largest absolute increase between 2023 and 2024.
- Receivables Turnover
- The receivables turnover ratio decreased from 5.65 in 2021 to 5.48 in 2022, indicating a slightly slower collection of receivables relative to sales. A more pronounced decrease was observed in 2023, with the ratio falling to 4.93. This suggests a lengthening of the collection period or a potential increase in uncollectible accounts. The ratio experienced a modest recovery to 5.19 in 2024, but then declined again to 4.87 in 2025. This most recent decrease suggests the trend of slower receivables collection is continuing.
- The consistent increase in net trade receivables, coupled with the fluctuating but generally declining receivables turnover ratio, suggests that the company is extending more credit to its customers, or experiencing difficulties in collecting outstanding balances, or a combination of both. The increase in sales in 2024 did not translate into a proportional increase in receivables turnover, further supporting this observation.
The observed trends warrant further investigation into the company’s credit policies, collection procedures, and the aging of its accounts receivable. A deeper analysis of these factors is necessary to determine the underlying causes of the declining receivables turnover and to assess any potential impact on the company’s financial health.
Payables Turnover
Bristol-Myers Squibb Co., payables turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of products sold, excludes amortization of acquired intangible assets | 13,936) | 13,968) | 10,693) | 10,137) | 9,940) | |
| Accounts payable | 3,575) | 3,602) | 3,259) | 3,040) | 2,949) | |
| Short-term Activity Ratio | ||||||
| Payables turnover1 | 3.90 | 3.88 | 3.28 | 3.33 | 3.37 | |
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | 5.07 | 5.74 | 5.54 | 5.94 | 6.05 | |
| Amgen Inc. | 5.09 | 6.74 | 5.32 | 4.08 | 4.72 | |
| Danaher Corp. | 5.45 | 5.52 | 5.58 | 5.45 | 4.48 | |
| Eli Lilly & Co. | 2.05 | 2.61 | 2.73 | 3.43 | 4.38 | |
| Gilead Sciences Inc. | 8.72 | 7.50 | 11.81 | 6.25 | 9.36 | |
| Johnson & Johnson | 2.52 | 2.66 | 2.76 | 2.66 | 2.70 | |
| Merck & Co. Inc. | 3.72 | 3.72 | 4.11 | 4.08 | 2.96 | |
| Pfizer Inc. | 3.07 | 3.17 | 3.72 | 5.04 | 5.53 | |
| Regeneron Pharmaceuticals Inc. | 2.24 | 2.50 | 2.99 | 2.65 | 4.32 | |
| Thermo Fisher Scientific Inc. | 7.27 | 8.18 | 8.97 | 7.67 | 6.83 | |
| Vertex Pharmaceuticals Inc. | 3.58 | 3.71 | 3.46 | 3.55 | 4.64 | |
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.72 | 4.08 | 4.25 | 4.28 | 4.23 | |
| Payables Turnover, Industry | ||||||
| Health Care | 6.15 | 6.10 | 5.97 | 5.79 | 5.84 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Payables turnover = Cost of products sold, excludes amortization of acquired intangible assets ÷ Accounts payable
= 13,936 ÷ 3,575 = 3.90
2 Click competitor name to see calculations.
The accounts payable activity, as measured by payables turnover, demonstrates a generally stable pattern with a slight upward trend over the five-year period. Cost of products sold, the denominator in the payables turnover calculation, exhibits consistent growth, while accounts payable fluctuates with a corresponding, though less pronounced, increase.
- Payables Turnover
- Payables turnover decreased from 3.37 in 2021 to 3.28 in 2023, indicating a slightly lengthening period for settling obligations to suppliers. However, a notable increase is observed in 2024 and 2025, with the ratio reaching 3.88 and 3.90 respectively. This suggests improved efficiency in managing and paying suppliers during these years.
- Cost of Products Sold
- Cost of products sold increased steadily from US$9,940 million in 2021 to US$10,693 million in 2023. A significant jump occurred in 2024, reaching US$13,968 million, and remained relatively stable in 2025 at US$13,936 million. This growth suggests increased production activity or higher input costs over the period.
- Accounts Payable
- Accounts payable increased from US$2,949 million in 2021 to US$3,259 million in 2023, mirroring the growth in cost of products sold. A further increase to US$3,602 million was seen in 2024, followed by a slight decrease to US$3,575 million in 2025. The fluctuations in accounts payable appear to be correlated with the changes in cost of products sold, but the magnitude of change is smaller, contributing to the observed payables turnover trend.
The increase in payables turnover in the latter two years, despite the substantial rise in cost of products sold, suggests the company effectively managed its payment terms with suppliers or benefited from economies of scale in purchasing. The initial slight decline in payables turnover may have been a temporary effect related to specific supplier arrangements or changes in purchasing strategies.
Working Capital Turnover
Bristol-Myers Squibb Co., working capital turnover calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 29,390) | 29,780) | 31,770) | 27,273) | 33,262) | |
| Less: Current liabilities | 23,417) | 23,774) | 22,262) | 21,890) | 21,868) | |
| Working capital | 5,973) | 6,006) | 9,508) | 5,383) | 11,394) | |
| Net product sales | 46,756) | 46,778) | 43,778) | 44,671) | 45,055) | |
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | 7.83 | 7.79 | 4.60 | 8.30 | 3.95 | |
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | 9.85 | 5.40 | 2.25 | 3.82 | 3.37 | |
| Danaher Corp. | 4.13 | 8.85 | 4.22 | 4.20 | 8.40 | |
| Eli Lilly & Co. | 3.19 | 10.32 | — | 31.84 | 8.33 | |
| Gilead Sciences Inc. | 4.43 | 3.99 | 5.61 | 8.42 | 8.54 | |
| Johnson & Johnson | 62.88 | 15.94 | 11.81 | — | 5.95 | |
| Merck & Co. Inc. | 4.28 | 6.19 | 9.29 | 5.16 | 7.62 | |
| Pfizer Inc. | 10.58 | 8.64 | — | 11.09 | 4.83 | |
| Regeneron Pharmaceuticals Inc. | 1.05 | 0.97 | 0.82 | 0.96 | 1.59 | |
| Thermo Fisher Scientific Inc. | 3.30 | 4.87 | 4.05 | 5.46 | 5.87 | |
| Vertex Pharmaceuticals Inc. | 1.64 | 1.83 | 0.93 | 0.85 | 1.02 | |
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.50 | 7.86 | 6.68 | 7.25 | 5.87 | |
| Working Capital Turnover, Industry | ||||||
| Health Care | 11.25 | 12.35 | 10.99 | 11.30 | 8.57 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Working capital turnover = Net product sales ÷ Working capital
= 46,756 ÷ 5,973 = 7.83
2 Click competitor name to see calculations.
The working capital turnover ratio exhibited considerable fluctuation between 2021 and 2025. Initial values decreased significantly from 2021 to 2022, followed by a period of relative stabilization and then a subsequent increase before leveling off. This suggests evolving efficiency in managing short-term assets and liabilities relative to sales.
- Working Capital
- Working capital decreased substantially from $11,394 million in 2021 to $5,383 million in 2022. It then increased to $9,508 million in 2023, before declining slightly to $6,006 million in 2024 and remaining relatively stable at $5,973 million in 2025. This pattern indicates potential shifts in short-term financing strategies or changes in operational needs.
- Net Product Sales
- Net product sales experienced a minor decrease from $45,055 million in 2021 to $44,671 million in 2022, followed by a further decrease to $43,778 million in 2023. Sales then increased to $46,778 million in 2024 and remained consistent at $46,756 million in 2025. This suggests a recovery in sales following an initial decline.
- Working Capital Turnover Ratio
- The working capital turnover ratio decreased from 3.95 in 2021 to 8.30 in 2022, representing a significant increase in efficiency. The ratio then decreased to 4.60 in 2023, before rising again to 7.79 in 2024 and stabilizing at 7.83 in 2025. The initial increase in 2022, coupled with the subsequent decline and recovery, suggests a period of operational adjustment and eventual stabilization in the utilization of working capital to generate sales. The ratio in 2024 and 2025 indicates a relatively efficient use of working capital, though lower than the peak observed in 2022.
The observed fluctuations in the working capital turnover ratio, in conjunction with the trends in working capital and net product sales, suggest a dynamic relationship between short-term asset and liability management and revenue generation. Further investigation into the underlying drivers of these changes may be warranted.
Average Inventory Processing Period
Bristol-Myers Squibb Co., average inventory processing period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | 5.18 | 5.46 | 4.02 | 4.33 | 4.74 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | 70 | 67 | 91 | 84 | 77 | |
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | 99 | 90 | 73 | 75 | 65 | |
| Amgen Inc. | 189 | 199 | 411 | 281 | 231 | |
| Danaher Corp. | 90 | 88 | 96 | 91 | 88 | |
| Eli Lilly & Co. | 454 | 329 | 298 | 237 | 194 | |
| Gilead Sciences Inc. | 104 | 100 | 100 | 97 | 89 | |
| Johnson & Johnson | 171 | 165 | 154 | 147 | 127 | |
| Merck & Co. Inc. | 148 | 147 | 144 | 124 | 159 | |
| Pfizer Inc. | 242 | 222 | 149 | 95 | 107 | |
| Regeneron Pharmaceuticals Inc. | 556 | 572 | 519 | 562 | 292 | |
| Thermo Fisher Scientific Inc. | 75 | 72 | 72 | 79 | 94 | |
| Vertex Pharmaceuticals Inc. | 373 | 287 | 214 | 156 | 143 | |
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 164 | 149 | 143 | 119 | 117 | |
| Average Inventory Processing Period, Industry | ||||||
| Health Care | 48 | 48 | 50 | 46 | 46 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 5.18 = 70
2 Click competitor name to see calculations.
The period under review demonstrates fluctuations in inventory management efficiency. Specifically, the average inventory processing period exhibited an increasing trend initially, followed by a subsequent decrease.
- Average Inventory Processing Period
- The average inventory processing period lengthened from 77 days in 2021 to 91 days in 2023, indicating a slower rate of inventory conversion into sales during this timeframe. This suggests a potential build-up of inventory or a decline in sales velocity. However, a notable shift occurred in 2024, with the period decreasing to 67 days. This improvement continued modestly into 2025, reaching 70 days. The reduction in processing period from 2023 to 2024 implies improved inventory management practices, increased sales, or a combination of both.
The changes in the average inventory processing period correlate with the inventory turnover ratio. A decreasing inventory turnover, observed from 2021 to 2023, aligns with the lengthening processing period. Conversely, the increase in inventory turnover from 2023 to 2025 corresponds with the shortening of the average inventory processing period. This suggests a strong relationship between these two metrics.
The most recent two years (2024 and 2025) indicate a stabilization of inventory management, with the average processing period remaining relatively consistent. Further investigation would be required to determine the sustainability of this improvement and the underlying drivers of these changes.
Average Receivable Collection Period
Bristol-Myers Squibb Co., average receivable collection period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | 4.87 | 5.19 | 4.93 | 5.48 | 5.65 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | 75 | 70 | 74 | 67 | 65 | |
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | 75 | 71 | 75 | 71 | 65 | |
| Amgen Inc. | 99 | 77 | 99 | 82 | 74 | |
| Danaher Corp. | 58 | 54 | 60 | 57 | 57 | |
| Eli Lilly & Co. | 99 | 89 | 97 | 88 | 86 | |
| Gilead Sciences Inc. | 62 | 56 | 63 | 65 | 61 | |
| Johnson & Johnson | 67 | 61 | 64 | 62 | 59 | |
| Merck & Co. Inc. | 66 | 58 | 63 | 58 | 69 | |
| Pfizer Inc. | 69 | 66 | 69 | 40 | 51 | |
| Regeneron Pharmaceuticals Inc. | 146 | 160 | 158 | 160 | 137 | |
| Thermo Fisher Scientific Inc. | 73 | 70 | 70 | 66 | 74 | |
| Vertex Pharmaceuticals Inc. | 62 | 53 | 58 | 59 | 55 | |
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 76 | 69 | 74 | 63 | 66 | |
| Average Receivable Collection Period, Industry | ||||||
| Health Care | 48 | 46 | 48 | 44 | 46 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.87 = 75
2 Click competitor name to see calculations.
An examination of the short-term activity ratios reveals a fluctuating pattern in the average receivable collection period between 2021 and 2025. While receivables turnover demonstrates some variability, the collection period consistently trends towards longer durations.
- Receivables Turnover
- The receivables turnover ratio decreased from 5.65 in 2021 to 5.48 in 2022, indicating a slightly slower rate of converting receivables into cash. A further decline to 4.93 was observed in 2023, representing the lowest value within the observed period. The ratio experienced a modest recovery to 5.19 in 2024, but subsequently decreased again to 4.87 in 2025. This overall downward trend suggests a potential weakening in the efficiency of collecting receivables.
- Average Receivable Collection Period
- The average receivable collection period increased from 65 days in 2021 to 67 days in 2022, suggesting a slight lengthening in the time required to collect payments. This trend continued with a more substantial increase to 74 days in 2023. A slight decrease to 70 days occurred in 2024, but the period extended again to 75 days in 2025, representing the longest collection period observed. The consistent increase over the five-year period indicates a growing delay in receiving cash from credit sales.
- Relationship between Ratios
- The inverse relationship between the receivables turnover and the average collection period is evident. As receivables turnover decreases, the average collection period increases, and vice versa. This confirms that a slower rate of converting receivables into cash directly translates to a longer time to collect outstanding balances. The observed trends suggest a potential need to evaluate credit policies and collection procedures to improve efficiency.
In summary, the analysis indicates a gradual deterioration in the efficiency of receivables management, as evidenced by the declining receivables turnover and increasing average collection period. Continued monitoring of these ratios is recommended to identify the underlying causes and implement appropriate corrective actions.
Operating Cycle
Bristol-Myers Squibb Co., operating cycle calculation, comparison to benchmarks
No. days
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 70 | 67 | 91 | 84 | 77 | |
| Average receivable collection period | 75 | 70 | 74 | 67 | 65 | |
| Short-term Activity Ratio | ||||||
| Operating cycle1 | 145 | 137 | 165 | 151 | 142 | |
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | 174 | 161 | 148 | 146 | 130 | |
| Amgen Inc. | 288 | 276 | 510 | 363 | 305 | |
| Danaher Corp. | 148 | 142 | 156 | 148 | 145 | |
| Eli Lilly & Co. | 553 | 418 | 395 | 325 | 280 | |
| Gilead Sciences Inc. | 166 | 156 | 163 | 162 | 150 | |
| Johnson & Johnson | 238 | 226 | 218 | 209 | 186 | |
| Merck & Co. Inc. | 214 | 205 | 207 | 182 | 228 | |
| Pfizer Inc. | 311 | 288 | 218 | 135 | 158 | |
| Regeneron Pharmaceuticals Inc. | 702 | 732 | 677 | 722 | 429 | |
| Thermo Fisher Scientific Inc. | 148 | 142 | 142 | 145 | 168 | |
| Vertex Pharmaceuticals Inc. | 435 | 340 | 272 | 215 | 198 | |
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 240 | 218 | 217 | 182 | 183 | |
| Operating Cycle, Industry | ||||||
| Health Care | 96 | 94 | 98 | 90 | 92 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 70 + 75 = 145
2 Click competitor name to see calculations.
The operating cycle lengthened from 142 days in 2021 to 165 days in 2023, before decreasing to 137 days in 2024 and subsequently increasing to 145 days in 2025. This indicates a shift in the time required to convert raw materials into cash from sales. A closer examination of the components reveals the drivers of this overall trend.
- Average Inventory Processing Period
- The average inventory processing period exhibited an increasing trend from 77 days in 2021 to 91 days in 2023. This suggests a slower turnover of inventory during this period. However, a notable decrease to 67 days occurred in 2024, followed by a slight increase to 70 days in 2025. This recent decline may indicate improved inventory management practices or increased sales velocity.
- Average Receivable Collection Period
- The average receivable collection period demonstrated a consistent upward trend, increasing from 65 days in 2021 to 75 days in 2025. This suggests a lengthening in the time taken to collect payments from customers. The increase is relatively gradual, but persistent, and could be attributable to changes in credit terms, customer payment behavior, or collection efficiency.
The operating cycle’s increase between 2021 and 2023 was primarily driven by the lengthening inventory processing period. The subsequent decrease in the operating cycle in 2024 was largely due to the significant reduction in the average inventory processing period, partially offsetting the continued increase in the receivable collection period. The slight increase in the operating cycle in 2025 reflects the combined effect of a minor increase in the inventory processing period and a further increase in the receivable collection period. Continued monitoring of these trends is recommended to assess potential impacts on working capital management and cash flow.
Average Payables Payment Period
Bristol-Myers Squibb Co., average payables payment period calculation, comparison to benchmarks
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | 3.90 | 3.88 | 3.28 | 3.33 | 3.37 | |
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | 94 | 94 | 111 | 109 | 108 | |
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | 72 | 64 | 66 | 61 | 60 | |
| Amgen Inc. | 72 | 54 | 69 | 90 | 77 | |
| Danaher Corp. | 67 | 66 | 65 | 67 | 82 | |
| Eli Lilly & Co. | 178 | 140 | 134 | 106 | 83 | |
| Gilead Sciences Inc. | 42 | 49 | 31 | 58 | 39 | |
| Johnson & Johnson | 145 | 137 | 132 | 137 | 135 | |
| Merck & Co. Inc. | 98 | 98 | 89 | 89 | 123 | |
| Pfizer Inc. | 119 | 115 | 98 | 72 | 66 | |
| Regeneron Pharmaceuticals Inc. | 163 | 146 | 122 | 138 | 84 | |
| Thermo Fisher Scientific Inc. | 50 | 45 | 41 | 48 | 53 | |
| Vertex Pharmaceuticals Inc. | 102 | 98 | 106 | 103 | 79 | |
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 98 | 90 | 86 | 85 | 86 | |
| Average Payables Payment Period, Industry | ||||||
| Health Care | 59 | 60 | 61 | 63 | 63 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.90 = 94
2 Click competitor name to see calculations.
The average payables payment period exhibited a generally increasing trend from 2021 to 2023, followed by a decrease in the subsequent two years. Simultaneously, the payables turnover ratio demonstrated a contrasting pattern, declining from 2021 to 2023 before increasing in 2024 and 2025.
- Average Payables Payment Period
- The average payables payment period lengthened from 108 days in 2021 to 111 days in 2023, indicating a slower rate of payment to suppliers over this period. This could be attributable to various factors, including negotiating extended payment terms with suppliers or a shift in procurement strategies. However, a notable decrease occurred in 2024 and 2025, with the period falling to 94 days in both years. This suggests a return to faster payment processing or a change in supplier relationships, potentially to capitalize on early payment discounts or strengthen supplier relations.
- Payables Turnover Ratio
- The payables turnover ratio decreased from 3.37 in 2021 to 3.28 in 2023. A declining ratio aligns with the increasing payment period, as it signifies that the company is taking longer to pay its suppliers, resulting in fewer turnover cycles within the year. The ratio then increased to 3.88 in 2024 and remained relatively stable at 3.90 in 2025. This increase corresponds with the reduction in the average payables payment period, indicating a more efficient use of trade credit and a faster cycle of paying suppliers.
The observed changes in both ratios suggest a dynamic relationship with supplier management and potentially, the company’s cash flow strategies. The recent trend towards faster payment processing, as evidenced by the 2024 and 2025 figures, may indicate a deliberate effort to optimize working capital management.
Cash Conversion Cycle
Bristol-Myers Squibb Co., cash conversion cycle calculation, comparison to benchmarks
No. days
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | 70 | 67 | 91 | 84 | 77 | |
| Average receivable collection period | 75 | 70 | 74 | 67 | 65 | |
| Average payables payment period | 94 | 94 | 111 | 109 | 108 | |
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | 51 | 43 | 54 | 42 | 34 | |
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | 102 | 97 | 82 | 85 | 70 | |
| Amgen Inc. | 216 | 222 | 441 | 273 | 228 | |
| Danaher Corp. | 81 | 76 | 91 | 81 | 63 | |
| Eli Lilly & Co. | 375 | 278 | 261 | 219 | 197 | |
| Gilead Sciences Inc. | 124 | 107 | 132 | 104 | 111 | |
| Johnson & Johnson | 93 | 89 | 86 | 72 | 51 | |
| Merck & Co. Inc. | 116 | 107 | 118 | 93 | 105 | |
| Pfizer Inc. | 192 | 173 | 120 | 63 | 92 | |
| Regeneron Pharmaceuticals Inc. | 539 | 586 | 555 | 584 | 345 | |
| Thermo Fisher Scientific Inc. | 98 | 97 | 101 | 97 | 115 | |
| Vertex Pharmaceuticals Inc. | 333 | 242 | 166 | 112 | 119 | |
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 142 | 128 | 131 | 97 | 97 | |
| Cash Conversion Cycle, Industry | ||||||
| Health Care | 37 | 34 | 37 | 27 | 29 | |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 70 + 75 – 94 = 51
2 Click competitor name to see calculations.
An examination of short-term operating activity reveals shifts in the management of inventory, receivables, and payables, ultimately impacting the cash conversion cycle over the five-year period. Generally, the initial years demonstrate increasing durations for inventory and receivables, while payables remained relatively stable, leading to a lengthening cash conversion cycle. More recent years show some stabilization and even improvement in certain areas.
- Average Inventory Processing Period
- The average time to process inventory increased from 77 days in 2021 to a peak of 91 days in 2023. A subsequent decrease to 67 days in 2024 was observed, followed by a slight increase to 70 days in 2025. This suggests potential inefficiencies in inventory management during 2022 and 2023, with some improvement in 2024, though not a return to the 2021 level. The 2025 value indicates this improvement may not be sustained.
- Average Receivable Collection Period
- The average receivable collection period exhibited a consistent upward trend from 65 days in 2021 to 75 days in 2025. This indicates a lengthening of the time required to collect payments from customers. The increase, while gradual, suggests a potential need to review credit policies or collection procedures.
- Average Payables Payment Period
- The average payables payment period remained relatively stable between 108 and 111 days from 2021 to 2023. A notable decrease to 94 days occurred in 2024 and was maintained through 2025. This suggests a potential shift in supplier negotiations or payment terms, providing some flexibility in cash flow management.
- Cash Conversion Cycle
- The cash conversion cycle increased from 34 days in 2021 to 54 days in 2023, reflecting the combined effect of increasing inventory and receivable periods, offset partially by stable payables. A decrease to 43 days in 2024 was observed, followed by an increase to 51 days in 2025. The cycle’s movement mirrors the trends in its component parts, indicating that improvements in payables management in 2024 were partially offset by increases in inventory processing and receivable collection times. The 2025 value suggests the positive impact of the 2024 changes is diminishing.
Overall, the trends suggest a potential challenge in efficiently managing working capital. While improvements were seen in payables management in the later years, the lengthening receivable collection period and fluctuating inventory processing period continue to impact the cash conversion cycle. Continued monitoring of these ratios is recommended to identify areas for operational improvement.